<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput xmlns:ns2="local" id="72762"><DrugName>NT-KO-012</DrugName><DrugSynonyms><Name><Value>NT-KO-012</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1063484">Neurotec Pharma SL</CompanyOriginator><CompaniesSecondary><Company id="1063484">Neurotec Pharma SL</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1063484" type="Company"><TargetEntity id="5005769864" type="organizationId">Neurotec Pharma SL</TargetEntity></SourceEntity><SourceEntity id="233" type="ciIndication"><TargetEntity id="10053643" type="MEDDRA"></TargetEntity><TargetEntity id="D019636" type="MeSH"></TargetEntity><TargetEntity id="-1502359765" type="omicsDisease"></TargetEntity><TargetEntity id="160" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3537" type="ciIndication"><TargetEntity id="10029240" type="MEDDRA"></TargetEntity><TargetEntity id="D009443" type="MeSH"></TargetEntity><TargetEntity id="-159547265" type="omicsDisease"></TargetEntity><TargetEntity id="1832" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="233">Neurodegenerative disease</Indication><Indication id="3537">Neuritis</Indication></IndicationsSecondary><ActionsSecondary><Action id="1615">Neuroprotectant</Action><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2017-08-30T09:14:57.000Z</LastModificationDate><ChangeDateLast>2014-10-28T00:00:00.000Z</ChangeDateLast><AddedDate>2011-07-28T12:22:49.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1063484" linkType="Company"&gt;Neurotec Pharma&lt;/ulink&gt; was investigating NT-KO-012, an undisclosed repurposed therapeutic which acts by inhibiting microglial reactivity, for the potential oral treatment of neuroinflammation and neurodegeneration. In July 2011, NT-KO-012 was listed as being in preclinical development [&lt;ulink linkID="1210708" linkType="Reference"&gt;1210708&lt;/ulink&gt;].  In February 2013, the company's strategy involved seeking to outlicense its drugs [&lt;ulink linkID="1366646" linkType="Reference"&gt;1366646&lt;/ulink&gt;]. However, by September 2014; Neurotec Pharma had filed for voluntary bankruptcy and all development by the company had been discontinued [&lt;ulink linkID="1732744" linkType="Reference"&gt;1732744&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1063484">Neurotec Pharma SL</Company><Country id="ES">Spain</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3537">Neuritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-09-26T00:00:00.000Z</StatusDate><Source id="1732744" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1063484">Neurotec Pharma SL</Company><Country id="ES">Spain</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="233">Neurodegenerative disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-09-26T00:00:00.000Z</StatusDate><Source id="1732744" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1063484">Neurotec Pharma SL</Company><Country id="ES">Spain</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="233">Neurodegenerative disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-07-28T00:00:00.000Z</StatusDate><Source id="1210708" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1063484">Neurotec Pharma SL</Company><Country id="ES">Spain</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3537">Neuritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-07-28T00:00:00.000Z</StatusDate><Source id="1210708" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput>